About Next Interactions
At Next Interactions, Inc., we apply the unique expertise of our team and our class-leading platform technologies to your biotech research and development problems.
Services
We offer a suite of services comprising protein-protein interaction (PPI) screens, protein engineering and functional assays. Our clients are in pharma, biotech and academic research.
We use Next-Generation Sequencing (NGS) as the readout, resulting in more complete datasets. Our thoroughly redesigned Y2H system components provide more quantitative and precise measurements of binding partner interactions than conventional Y2H assays. Our platform technology enables us to decipher the full coverage of protein-protein interactions (PPIs). These discoveries have been applied to problems in human health, energy, food security and sustainability.
Why us?
Our team consists of scientists and entrepreneurs with extensive experience in protein interaction technologies, cell signaling and systems biology. We use our platform technology and expertise to decipher more complete and accurate protein-protein interactomes to accelerate your research and product development.
How can we help you?
We have helped our clients with a variety of complex, high impact, difficult projects including the screening for novel tumor suppressor targets, PPIs in hearing disorders, interaction mappings for novel isoforms, plant interaction networks, among other state-of-the-art projects.
Management Team
BERNHARD SUTER
CEO and Co-Founder
I use my expertise in systems biology, yeast genetics and assay development to build perfect solutions for interaction screens. Prior to Next, I held academic positions at the UC Berkeley, the University of Toronto and in Germany
RICH YU
COO and Co-Founder
As a biotech entrepreneur, former venture capital partner and biotech incubator manager, and scientist with experience in protein engineering and systems and synthetic biology, I contribute to technical development, company growth, and operations management at Next Interactions.
GUSTAVO PESCE
CSO and Co-Founder
As Chief Scientific Officer, I always have my eye on the next discovery. Whether it is for our customers or developing our proprietary antibody discovery platform, I lead the company’s development of next-gen PPI assays.
Our Team
RODRIGO BALTANAS
Senior Scientist
I came from Argentina and joined the amazing Next Interactions team to develop novel immunological treatments for human pathologies. I treasure the multidisciplinary nature of our work.
YONGWON KWON
Senior Scientist
I joined Next Interactions to develop new yeast two-hybrid methods. Prior to joining Next, I discovered novel cancer biomarkers using proteomics and genomics technologies at LBNL and the UCSF Cancer Center. I earned my doctoral degree at Kyoto University, Japan.
STEPHANIE LOPEZ
Scientist
Yeast are a versatile, powerful organism for tackling modern research problems. I love using them as a platform for developing membrane protein technologies at Next Interactions. Previous to joining the Next Interactions team, I studied protein engineering at UC Berkeley.
ANDREW MENDELSOHN
Advisor & Co-founder
I bring 30 years of expertise in molecular, cell and synthetic biology as a biotechnology researcher and serial entrepreneur. I also serve as the Director of Molecular Biology at a Silicon Valley biotechnology incubator and Director of Research at the Regenerative Sciences Institute.
KATE SOKOLINA
Scientist & Operations Manager
At Next, I split my time between research and keeping the lab running smoothly. I study human receptors and coordinate the company’s operational needs. Prior to joining Next, I studied proteomics of heart disease at the University of Toronto.
EVELIN SZAKAL
Director of Business Development
I am a business and science professional. Previously I was co-founder and director of corporate development at TheraBiol Inc. I hold a BS in economics, a Ph.D. in medical microbiology from Hungary and completed my postdoc at UCSF studying protein complexes.